All In Biotech

Drug Trial Radar · NCT07635914

A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant Hypertension

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Aprocitentan Tablets in the Treatment of Resistant Hypertension

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 382 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

382

Planned (sponsor's estimate)

Start

May 31, 2026

Primary completion

Dec 28, 2029

Study completion May 31, 2030

Sponsor

Sponsor type
Industry
First posted
Jun 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Aprocitentan tablets are currently the only endothelin dual receptor antagonist approved internationally for the treatment of resistant hypertension.This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of aprocitentan tablets(SYH9108) in patients with treatment-resistant hypertension (rHTN)

Conditions

  • Resistant Hypertension

Interventions

  • Aprocitentan tablets(SYH9108)Drug

    For oral administration

  • PlaceboDrug

    For oral administration. The placebo is identical to aprocitentan tablets(SYH9108) in appearance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Sitting Systolic Blood Pressure (SiSBP) after 8 weeks of treatment.Time frame: Baseline and week 8

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.